Are Utilities Stocks Lagging ENGIE - Sponsored ADR (ENGIY) This Year?
ENGIE - Sponsored ADR is a member of the Utilities sector. This group includes 106 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. ENGIE - Sponsored ADR is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ENGIY's full-year earnings has moved 19.6% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Our latest available data shows that ENGIY has returned about 46.6% since the start of the calendar year. Meanwhile, the Utilities sector has returned an average of 8.1% on a year-to-date basis. As we can see, ENGIE - Sponsored ADR is performing better than its sector in the calendar year.
Another Utilities stock, which has outperformed the sector so far this year, is National Grid (NGG). The stock has returned 23.7% year-to-date.
The consensus estimate for National Grid's current year EPS has increased 5.6% over the past three months. The stock currently has a Zacks Rank #1 (Strong Buy).
To break things down more, ENGIE - Sponsored ADR belongs to the Utility - Electric Power industry, a group that includes 60 individual companies and currently sits at #83 in the Zacks Industry Rank. Stocks in this group have gained about 8% so far this year, so ENGIY is performing better this group in terms of year-to-date returns. National Grid is also part of the same industry.
ENGIE - Sponsored ADR and National Grid could continue their solid performance, so investors interested in Utilities stocks should continue to pay close attention to these stocks.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ENGIE - Sponsored ADR (ENGIY) : Free Stock Analysis Report
National Grid Transco, PLC (NGG) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Are Investors Undervaluing Bayer (BAYRY) Right Now?
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers. Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks. Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now. One stock to keep an eye on is Bayer (BAYRY). BAYRY is currently holding a Zacks Rank #2 (Buy) and a Value grade of A. The stock is trading with P/E ratio of 5.68 right now. For comparison, its industry sports an average P/E of 13.70. Over the past 52 weeks, BAYRY's Forward P/E has been as high as 6.45 and as low as 3.72, with a median of 5.20. These figures are just a handful of the metrics value investors tend to look at, but they help show that Bayer is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, BAYRY feels like a great value stock at the moment. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Reasons to Include Curtiss-Wright Stock in Your Portfolio Right Now
Curtiss-Wright Corp. CW benefits from rising commercial nuclear aftermarket sales and consistent shareholder-focused initiatives that have played a pivotal role in strengthening the company's overall performance. Given its significant growth, CW is a good investment opportunity in the Zacks Aerospace Defense Equipment us focus on the factors that make this Zacks Rank #2 (Buy) company a strong investment pick at the moment. Growth Outlook & Surprise History of CW The Zacks Consensus Estimate for CW's 2025 earnings per share (EPS) has increased 1.8% to $12.86 per share over the past 30 Zacks Consensus Estimate for Curtiss-Wright's 2025 revenues stands at $3.42 billion, which indicates growth of 9.5%.The company's long-term (three to five years) earnings growth rate is 12.5%. CW surpassed expectations in the last four reported quarters and delivered an average earnings surprise of 9.34%. Curtiss-Wright's Return on Equity Return on equity (ROE) indicates how efficiently a company utilizes funds to generate higher returns. Currently, Curtiss-Wright's ROE is 18.34%, higher than the industry average of 8.29%. This indicates that the company has been utilizing funds more constructively than its peers in the aerospace defense equipment industry. CW's Shareholder-Friendly Actions CW has been increasing its shareholder value through regular dividend payments. Currently, the company's quarterly dividend is 24 cents per share, resulting in an annualized dividend of 96 cents. The company's current dividend yield is 0.20%, better than the industry's average of 0.16%. Debt Structure of CW Currently, Curtiss-Wright's total debt to capital is 26.11%, much better than the industry's average of 51.51%.CW's times interest earned ratio (TIE) at the end of the second quarter of 2025 was 14.2. The ratio, being greater than one, reflects the company's ability to meet future interest obligations without difficulties. CW's Nuclear Operations Remain Strong The United States continues to be a key market for Curtiss-Wright's nuclear power growth. In the second quarter of 2025, the company saw a sharp increase in commercial nuclear aftermarket sales. CW is actively working with designers of reactors exceeding 300 megawatts to secure roles in developing essential systems and equipment, positioning itself for sustained growth in both the U.S. and global nuclear markets. CW Stock Price Performance In the past six months, Curtiss-Wright stock has rallied 44.8% compared with the industry's growth of 22%. Image Source: Zacks Investment Research Other Stocks to Consider A few other top-ranked stocks from the same industry are Sky Harbour Group SKYH, Woodward, Inc. WWD and Moog Inc. (MOG.A), each carrying a Zacks Rank #2 at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks delivered an average earnings surprise of 7.41% in the past four quarters. The Zacks Consensus Estimate for the company's total revenues for 2025 stands at $31.1 million, which indicates year-over-year growth of 110.5%.Woodward's long-term earnings growth rate is 13.9%. The Zacks Consensus Estimate for WWD's fiscal 2025 sales is pegged at $3.48 billion, which implies an improvement of 4.8%.Moog delivered an average earnings surprise of 12.20% in the past four quarters. The Zacks Consensus Estimate for the company's total revenues for fiscal 2025 stands at $3.78 billion, which suggests year-over-year growth of 4.8%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Curtiss-Wright Corporation (CW) : Free Stock Analysis Report Woodward, Inc. (WWD) : Free Stock Analysis Report Moog Inc. (MOG.A) : Free Stock Analysis Report Sky Harbour Group Corporation (SKYH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
VCYT Stock Gains on Q2 Earnings and Revenue Beat, Margins Up
Veracyte, Inc. VCYT delivered second-quarter 2025 adjusted earnings of 44 cents per share, which marked a stupendous improvement of 46.7% from the year-ago period's figure of 30 cents. The bottom line beat the Zacks Consensus Estimate by 41.9%. The company's GAAP loss per share (EPS) was 1 cent compared to the year-ago period's earnings of 7 cents per share. Following the earnings announcement, VCYT's share price gained 15.5% last Thursday. VCYT's Q2 Revenues Revenues increased 13.8% year over year to $130.2 million, which outpaced the Zacks Consensus Estimate by 7.1%. VCYT's Q2 Segmental Details Testing revenues totaled $122.3 million, up 14% year over year. This rise was mainly due to Decipher and Afirma revenue growth of 24% and 5%, respectively. Testing volume improved 18% year over year to 42,441 tests. Product revenues fell 8% year over year to $3.6 million. Biopharmaceutical and other revenues of $4.3 million reflected a 21% increase from the prior-year quarter's figure. Margins The total cost of revenues (product, testing, biopharmaceutical and other) was $37.7 million, up 12.3% year over year. The gross profit rose 14.4% to $92.4 million. The gross margin expanded 38 basis points (bps) to 71%. Selling and marketing expenses rose 4.5% to $25.3 million, while general and administrative expenses increased 1.8% to $32.3 million. R&D expenses totaled $16.3 million, down 1.2% year over year. The adjusted operating margin was 14.2%, which expanded 689 bps year over year. VCYT's Cash, Capital Structure and Solvency Veracyte exited second-quarter 2025 with cash and cash equivalents of $219.5 million compared with $186.1 million at the end of the first quarter. The cumulative net cash provided from operating activities at the end of the reported quarter was $39 million compared with $20.6 million a year ago. VCYT's 2025 Guidance Veracyte raised its full-year 2025 testing revenue guidance. The company expects testing revenues to be in the range of $477-$483 million (up from $470-$480 million), implying 14% to 15% year-over-year growth. Veracyte, Inc. Price, Consensus and EPS Surprise Veracyte, Inc. price-consensus-eps-surprise-chart | Veracyte, Inc. Quote Given the resolution of the French subsidiary proceedings, the company initiated full-year 2025 total revenue guidance of $496-$504 million, implying 11% to 13% year-over-year growth. The Zacks Consensus Estimate for the metric is currently pegged at $501.1 billion. The company raised guidance for adjusted EBITDA as a percentage of revenues. It is anticipated to be approximately 23.5% (up from the previous guidance of 22.5%). Our Take Veracyte reported better-than-expected second-quarter results, with its earnings and revenues surpassing their respective estimates. The company registered robust growth from its market-leading Decipher Prostate and Afirma tests. Meanwhile, the growth in Biopharmaceutical and other revenues was encouraging. Both margin expansion instills optimism among investors. In the second quarter, the company had some notable developments, including the launch of Decipher Prostate Metastatic Genomic Classifier for use in patients whose prostate cancer has spread beyond the primary tumor. Zacks Rank and Key Picks Veracyte currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks from the broader medical space are Medpace Holdings MEDP, GeneDx Holdings WGS and Cardinal Health CAH. Medpace Holdings, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2025 EPS of $3.1, which beat the Zacks Consensus Estimate by 3.33%. Revenues of $603.3 million topped the consensus mark by 11.48%. You can see the complete list of today's Zacks #1 Rank stocks here. MEDP has a historical five-year earnings growth rate of 30.9% compared with the S&P 500 composite's 10.1% growth. GeneDx Holdings, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter 2025 adjusted EPS of 50 cents, which exceeded the Zacks Consensus Estimate by a remarkable 400%. Revenues of $102.7 million surpassed the Zacks Consensus Estimate by 21.24%. WGS has an estimated earnings growth rate of 79.6% for 2026 compared with the industry's 18.6% growth. Cardinal Health, carrying a Zacks Rank #2 at present, posted third-quarter fiscal 2025 adjusted EPS of $2.35, which exceeded the Zacks Consensus Estimate by 9.3%. Revenues of $54.88 billion missed the Zacks Consensus Estimate by 0.3%. CAH has an estimated long-term earnings growth rate of 10.9% compared with the industry's 9.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Cardinal Health, Inc. (CAH) : Free Stock Analysis Report Veracyte, Inc. (VCYT) : Free Stock Analysis Report Medpace Holdings, Inc. (MEDP) : Free Stock Analysis Report GeneDx Holdings Corp. (WGS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
